Gender Aspects of the Role of the Metabolic Syndrome as a Risk Factor for Cardiovascular Disease

Gender Medicine

Volumn 4, Issue SUPPL. 2, 2007, Pages

  Regitz Zagrosek, Vera ^a,b   Lehmkuhl, Elke ^a,b   Mahmoodzadeh, Shokufeh ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DEUTSCHES HERZZENTRUM BERLIN   (Germany)

Author keywords

cardiovascular disease; gender differences; menopause; metabolic syndrome

Indexed keywords

ESTROGEN; SEX HORMONE; TESTOSTERONE;

AGE DISTRIBUTION; AGING; ARTICLE; ATHEROGENESIS; BIBLIOGRAPHIC DATABASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIAGNOSTIC VALUE; DYSLIPIDEMIA; GENDER BIAS; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HORMONAL REGULATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; LIPID METABOLISM; MEDICAL LITERATURE; MEDICAL RESEARCH; MENOPAUSE; METABOLIC SYNDROME X; OBESITY; OVARY POLYCYSTIC DISEASE; PREVALENCE; PRIORITY JOURNAL; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

ADULT; AGED; CARDIOVASCULAR DISEASES; FEMALE; GENDER IDENTITY; HUMANS; MALE; MENOPAUSE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS; SEX FACTORS;

EID: 37449028953     PISSN: 15508579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1550-8579(07)80056-8     Document Type: Article

References (98)

1. Reaven G. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
2. Grundy S., Pasternak R., Greenland P., et al. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 100 (1999) 1481-1492
3. Balkau B., Charles M., and for the European Group for the Study of Insulin Resistance (EGIR). Comment on the provisional report from the WHO consultation. Diabet Med 16 (1999) 442-443
4. Alberti K., and Zimmet P. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15 (1998) 539-553
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
6. Einhorn D., Reaven G., Cobin R., et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 9 (2003) 237-252
7. Regitz-Zagrosek V., Lehmkuhl E., and Weickert M. Gender differences in the metabolic syndrome and their role for cardiovascular disease. [published correction appears in Clin Res Cardiol. 2006;95:147]. Clin Res Cardiol. 95 (2006) 136-147
8. Grundy S., Brewer Jr. H., Cleeman J., et al., for the American Heart Association and the National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109 (2004) 433-438
9. Rathmann W., Haastert B., Icks A., et al., for the KORA Survey 2000. High prevalence of undiagnosed diabetes mellitus in Southern Germany: Target populations for efficient screening. Diabetologia 46 (2003) 182-189
10. Ryden L., Standl E., Bartnik M., et al., for the Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and the Euopean Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary. Eur Heart J 28 (2007) 88-136
11. Hanefeld M., Koehler C., Fuecker K., et al., for the Impaired Glucose Tolerance for Atherosclerosis and Diabetes Study. Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: The Risk Factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes Study. Diabetes Care 26 (2003) 868-874
12. Lorenzo C., Okoloise M., Williams K., et al., for the San Antonio Heart Study. The metabolic syndrome as predictor of type 2 diabetes: The San Antonio heart study. Diabetes Care 26 (2003) 3153-3159
13. Alexander C., Landsman P., Teutsch S., Haffner S., and for the Third National Health and Nutrition Examination Survey (NHANES III) and the National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52 (2003) 1210-1214
14. Balkau B., Charles M., Drivsholm T., et al., for the European Group for the Study of Insulin Resistance (EGIR). Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 28 (2002) 364-376
15. Ford E., Giles W., and Dietz W. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 287 (2002) 356-359
16. Steinbaum S. The metabolic syndrome: An emerging health epidemic in women. Prog Cardiovasc Dis 46 (2004) 321-336
17. Pannier B., Thomas F., Eschwege E., et al. Cardiovascular risk markers associated with the metabolic syndrome in a large French population: The "SYMFONIE" study. Diabetes Metab 32 (2006) 467-474
18. Csaszar A., Kekes E., Abel T., et al. Prevalence of metabolic syndrome estimated by International Diabetes Federation criteria in a Hungarian population. Blood Press 15 (2006) 101-106
19. Lorenzo C., Serrano-Rios M., Martinez-Larrad M., et al. Central adiposity determines prevalence differences of the metabolic syndrome. Obes Res 11 (2003) 1480-1487
20. Williams C. Lipid metabolism in women. Proc Nutr Soc 63 (2004) 153-160
21. Tchernof A., Poehlman E., and Despres J. Body fat distribution, the menopause transition, and hormone replacement therapy. [retraction in: Halimi S, Guillausseau PJ. Diabetes Metab. 2006;32:285]. Diabetes Metab. 26 (2000) 12-20
22. Gambacciani M., Ciaponi M., Cappagli B., et al. Climacteric modifications in body weight and fat tissue distribution. Climacteric 2 (1999) 37-44
23. Poehlman E., Toth M., and Gardner A. Changes in energy balance and body composition at menopause: A controlled longitudinal study. [retraction in: Sox HC. Ann Intern Med. 2003;139:702]. Ann Intern Med. 123 (1995) 673-675
24. Carr M. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 88 (2003) 2404-2411
25. Mayes J., and Watson G. Direct effects of sex steroid hormones on adipose tissues and obesity. Obes Rev 5 (2004) 197-216
26. Wajchenberg B. Subcutaneous and visceral adipose tissue: Their relation to the metabolic syndrome. Endocr Rev 21 (2000) 697-738
27. Krotkiewski M., Bjorntorp P., Sjostrom L., and Smith U. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest 72 (1983) 1150-1162
28. Pedersen S., Kristensen K., Hermann P., et al. Estrogen controls lipolysis by up-regulating alpha2A-adrenergic receptors directly in human adipose tissue through the estrogen receptor alpha. Implications for the female fat distribution. J Clin Endocrinol Metab 89 (2004) 1869-1878
29. Lonnqvist F., Thorne A., Large V., and Arner P. Sex differences in visceral fat lipolysis and metabolic complications of obesity. Arterioscler Thromb Vasc Biol 17 (1997) 1472-1480
30. Van Harmelen V., Reynisdottir S., Eriksson P., et al. Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes 47 (1998) 913-917
31. Huang K., Lin R., Kormas N., et al. Plasma leptin is associated with insulin resistance independent of age, body mass index, fat mass, lipids, and pubertal development in nondiabetic adolescents. Int J Obes Relat Metab Disord 28 (2004) 470-475
32. Montague C., Prins J., Sanders L., et al. Depot- and sex-specific differences in human leptin mRNA expression: Implications for the control of regional fat distribution. Diabetes 46 (1997) 342-347
33. Ryo M., Nakamura T., Kihara S., et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 68 (2004) 975-981
34. Costacou T., Zgibor J., Evans R., et al. The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 48 (2004) 41-48
35. Laughlin G., Barrett-Connor E., Kritz-Silverstein D., and von Muhlen D. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: The Rancho Bernardo Study. J Clin Endocrinol Metab. 85 (2000) 645-651
36. Bjorntorp P. Metabolic difference between visceral fat and subcutaneous abdominal fat [in French]. Diabetes Metab 26 Suppl 3 (2000) 10-12
37. Valve R., Sivenius K., Miettinen R., et al. Two polymorphisms in the peroxisome proliferatoractivated receptor-γ gene are associated with severe overweight among obese women. J Clin Endocrinol Metab 84 (1999) 3708-3712
38. Regitz-Zagrosek V., Lehmkuhl E., Lehmkuhl H., and Hetzer R. Gender aspects in heart failure. Pathophysiology and medical therapy. Arch Mal Coeur Vaiss 97 (2004) 899-908
39. Nordmeyer J., Eder S., Mahmoodzadeh S., et al. Upregulation of myocardial estrogen receptors in human aortic stenosis. Circulation 110 (2004) 3270-3275
40. Peterson L., Herrero P., Schechtman K., et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 109 (2004) 2191-2196
41. Thomas F., Bean K., Pannier B., et al. Cardiovascular mortality in overweight subjects: The key role of associated risk factors. Hypertension 46 (2005) 654-659
42. Knopp R., Paramsothy P., Retzlaff B., et al. Gender differences in lipoprotein metabolism and dietary response: Basis in hormonal differences and implications for cardiovascular disease. Curr Atheroscler Rep 7 (2005) 472-479
43. Assmann G., Cullen P., and Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. [published correction appears in Circulation. 2002;105:900]. Circulation 105 (2002) 310-315
44. de Aloysio D., Gambacciani M., Meschia M., et al., for the Icarus Study Group. The effect of menopause on blood lipid and lipoprotein levels. Atherosclerosis 147 (1999) 147-153
45. Jensen J., Nilas L., and Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas 12 (1990) 321-331
46. Wilson P., D'Agostino R., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
47. Assmann G., and Schulte H. The importance of triglycerides: Results from the Prospective Cardiovascular Munster (PROCAM) Study. Eur J Epidemiol 8 Suppl 1 (1992) 99-103
48. Gasse C., Hense H., Stieber J., et al. Assessing hypertension management in the community: Trends of prevalence, detection, treatment, and control of hypertension in the MONICA Project, Augsburg 1984-1995. J Hum Hypertens 15 (2001) 27-36
49. Nickenig G. Should angiotensin II receptor blockers and statins be combined?. Circulation 110 (2004) 1013-1020
50. Fischer M., Baessler A., and Schunkert H. Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res 53 (2002) 672-677
51. Reckelhoff J. Gender differences in the regulation of blood pressure. Hypertension 37 (2001) 1199-1208
52. Pechere-Bertschi A., and Burnier M. Female sex hormones, salt, and blood pressure regulation. Am J Hypertens 17 (2004) 994-1001
53. Wang T., Larson M., Levy D., et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 90 (2002) 254-258
54. Rahmouni K., Correia M., Haynes W., and Mark A. Obesity-associated hypertension: New insights into mechanisms. Hypertension 45 (2005) 9-14
55. Faria A., Ribeiro Filho F., Gouveia Ferreira S., and Zanella M. Impact of visceral fat on blood pressure and insulin sensitivity in hypertensive obese women. Obes Res 10 (2002) 1203-1206
56. Cheurfa N., Reis A., Dubois-Laforgue D., et al. The Gly482Ser polymorphism in the peroxisome proliferator-activated receptor-γ coactivator-1 gene is associated with hypertension in type 2 diabetic men. Diabetologia 47 (2004) 1980-1983
57. Oberkofler H., Holzl B., Esterbauer H., et al. Peroxisome proliferator-activated receptor-γ coactivator-1 gene locus: Associations with hypertension in middle-aged men. Hypertension 41 (2003) 368-372
58. Kuznetsova T., Staessen J., Thijs L., et al., for the European Project on Genes in Hypertension (EPOGH) Investigators. Left ventricular mass in relation to genetic variation in angiotensin II receptors, renin system genes, and sodium excretion. Circulation 110 (2004) 2644-2650
59. Kannel W. Incidence and epidemiology of heart failure. Heart Fail Rev 5 (2000) 167-173
60. Conroy R., Pyorala K., Fitzgerald A., et al., for the SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J 24 (2003) 987-1003
61. The DECODE Study Group. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care 26 (2003) 61-69
62. Pomerleau J., McKeigue P., and Chaturvedi N. Relationships of fasting and postload glucose levels to sex and alcohol consumption. Are American Diabetes Association criteria biased against detection of diabetes in women? Diabetes Care 22 (1999) 430-433
63. Falkner B., Hulman S., and Kushner H. Gender differences in insulin-stimulated glucose utilization among African-Americans. Am J Hypertens 7 (1994) 948-952
64. Travers S., Jeffers B., and Eckel R. Insulin resistance during puberty and future fat accumulation. J Clin Endocrinol Metab 87 (2002) 3814-3818
65. Williams J., Zimmet P., Shaw J., et al. Gender differences in the prevalence of impaired fasting glycaemia and impaired glucose tolerance in Mauritius. Does sex matter? Diabet Med 20 (2003) 915-920
66. Goldstein B. Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol 90 (2002) 3G-10G
67. Ehm M., Karnoub M., Sakul H., et al., for the American Diabetes Association GENNID Study Group. Genetics of NIDDM. Genomewide search for type 2 diabetes susceptibility genes in four American populations. [published correction appears in Am J Hum Genet. 2002;70:284]. Am J Hum Genet. 66 (2000) 1871-1881
68. Pan W., Cedres L., Liu K., et al. Relationship of clinical diabetes and asymptomatic hyperglycemia to risk of coronary heart disease mortality in men and women. Am J Epidemiol 123 (1986) 504-516
69. Barrett-Connor E., and Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care 21 (1998) 1236-1239
70. Lundberg V., Stegmayr B., Asplund K., et al. Diabetes as a risk factor for myocardial infarction: Population and gender perspectives. J Intern Med 241 (1997) 485-492
71. Barrett-Connor E., Cohn B., Wingard D., and Edelstein S. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men The Rancho Bernardo Study. [published correction appears in JAMA. 1991;265:3249]?. JAMA 265 (1991) 627-631
72. Scheidt-Nave C., Barrett-Connor E., Wingard D., et al. Sex differences in fasting glycemia as a risk factor for ischemic heart disease death. Am J Epidemiol 133 (1991) 565-576
73. Thompson S., Kienast J., Pyke S., et al., for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 332 (1995) 635-641
74. Steinberg H., Paradisi G., Cronin J., et al. Type II diabetes abrogates sex differences in endothelial function in premenopausal women. Circulation 101 (2000) 2040-2046
75. Huxley R., Barzi F., and Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: Meta-analysis of 37 prospective cohort studies. BMJ 332 (2006) 73-78
76. Azziz R. Polycystic ovary syndrome, insulin resistance, and molecular defects of insulin signaling. J Clin Endocrinol Metab 87 (2002) 4085-4087
77. Bjorntorp P. Metabolic implications of body fat distribution. Diabetes Care 14 (1991) 1132-1143
78. Moran L., and Norman R. Understanding and managing disturbances in insulin metabolism and body weight in women with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 18 (2004) 719-736
79. Gambineri A., Pelusi C., Vicennati V., et al. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 26 (2002) 883-896
80. Eckel R., Grundy S., and Zimmet P. The metabolic syndrome. Lancet 365 (2005) 1415-1428
81. Mieres J., Shaw L., Arai A., et al., for the Cardiac Imaging Committee, Council on Clinical Cardiology; and the Cardiovascular Imaging and Intervention Committee, Council on Cardiovascular Radiology and Intervention, American Heart Association. Role of noninvasive testing in the clinical evaluation of women with suspected coronary artery disease: Consensus statement from the Cardiac Imaging Committee, Council on Clinical ardiology, and the Cardiovascular Imaging and Intervention Committee, Council on Cardiovascular Radiology and Intervention, American Heart Association. Circulation 111 (2005) 682-696
82. Granger J., Alexander B., Llinas M., et al. Pathophysiology of preeclampsia: Linking placental ischemia/hypoxia with microvascular dysfunction. Microcirculation 9 (2002) 147-160
83. Reckelhoff J., Yanes L., Iliescu R., et al. Testosterone supplementation in aging men and women: Possible impact on cardiovascular-renal disease. Am J Physiol Renal Physiol 289 (2005) F941-F948
84. Neugarten J., Acharya A., and Silbiger S. Effect of gender on the progression of nondiabetic renal disease: A meta-analysis. J Am Soc Nephrol 11 (2000) 319-329
85. Silbiger S., and Neugarten J. The role of gender in the progression of renal disease. Adv Ren Replace Ther 10 (2003) 3-14
86. Kalme T., Seppala M., Qiao Q., et al. Sex hormonebinding globulin and insulin-like growth factorbinding protein-1 as indicators of metabolic syndrome, cardiovascular risk, and mortality in elderly men. J Clin Endocrinol Metab 90 (2005) 1550-1556
87. Lindstedt G., Lundberg P., Lapidus L., et al. Low sexhormone-binding globulin concentration as independent risk factor for development of NIDDM. 12-Yr follow-up of population study of women in Gothenburg, Sweden. Diabetes 40 (1991) 123-128
88. Sundstrom J., Riserus U., Byberg L., et al. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: Prospective, population based cohort study. BMJ 332 (2006) 878-882
89. Kahn R., Buse J., Ferrannini E., Sten M., and for the American Diabetes Association and the European Association for the Study of Diabetes. The metabolic syndrome: Time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28 (2005) 2289-2304
90. Sundstrom J., Vallhagen E., Riserus U., et al. Risk associated with the metabolic syndrome versus the sum of its individual components. Diabetes Care 29 (2006) 1673-1674
91. Stern M., Williams K., Gonzalez-Villalpando C., et al. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease [published correction appears in Diabetes Care. 2005;28:238]? Diabetes Care 27 (2004) 2676-2681
92. Mogelvang R., Scharling H., and Jensen J. A simple linear model for the effect of changes in metabolic risk factors on coronary heart disease. J Intern Med 259 (2006) 561-568
93. Wannamethee S., Shaper A., Lennon L., and Morris R. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 165 (2005) 2644-2650
94. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 (2001) 683-689
95. Lakka H., Laaksonen D., Lakka T., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
96. Marroquin O., Kip K., Kelley D., et al., for the Women's Ischemia Syndrome Evaluation Investigators. Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: A report from the Women's Ischemia Syndrome Evaluation. Circulation 109 (2004) 714-721
97. Gibbons R., Balady G., Bricker J., et al., for the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). ACC/AHA 2002 guideline update for exercise testing: Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 106 (2002) 1883-1892
98. Mosca L., Banka C., Benjamin E., et al., for the Expert Panel/Writing Group; the American Academy of Physician Assistants; the American Association for Clinical Chemistry; the American Association of Cardiovascular and Pulmonary Rehabilitation; the American College of Chest Physicians; the American College of Emergency Physicians; the American Diabetes Association; the American Geriatrics Society; the American Society for Preventive Cardiology; the American Society of Echocardiography; the American Society of Nuclear Cardiology; the Association of Women's Health; Obstetric and Neonatal Nurses; the Global Alliance for Women's Health; Mended Hearts, Inc; the National Black Nurses Association; the National Black Women's Health Imperative; the National Women's Health Resource Center; the North American Menopause Society; the Partnership for Gender-Specific Medicine at Columbia University; the Preventive Cardiovascular Nurses Association; the Society for Vascular Medicine and Biology; the Society for Women's Health Research; the Society of Geriatric Cardiology; Women in Thoracic Surgery; WomenHeart; and the National Coalition for Women with Heart Disease. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 Update. J Am Coll Cardiol 49 (2007) 1230-1250